Current status and challenges of immunotherapy in ALK rearranged NSCLC

Rearrangements of the anaplastic lymphoma kinase (ALK) gene account for 5-6% in non-small cell lung cancer (NSCLC). ALK rearranged NSCLC is sensitive to ALK tyrosine kinase inhibitors (TKIs) but prone to drug resistance. Meanwhile, ALK rearranged NSCLC has poor response to single immunotherapy. Here...

Descripción completa

Detalles Bibliográficos
Autores principales: Qi, Rongbin, Yu, Yingying, Shen, Mo, Lv, Dongqing, He, Susu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9795041/
https://www.ncbi.nlm.nih.gov/pubmed/36591504
http://dx.doi.org/10.3389/fonc.2022.1016869

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9795041/
https://www.ncbi.nlm.nih.gov/pubmed/36591504
http://dx.doi.org/10.3389/fonc.2022.1016869

Ejemplares similares